Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

s: Cost of product sales

4,7842,78213,5599,638 Research and development

4,1186,31725,61236,561 Selling, general and administrative

17,07015,71868,99658,652 Intangible asset amortization

1,8622,0577,8257,668 Total operating expenses

27,83426,874115,992112,519 Income from operations

25,53511,41057,78915,930 Interest income

15634 Interest expense

(1,077)(5,762)(12,728)(22,796) Other expense

--(2)(4) Loss on extinguishment of debt

--(12,287)- Net income (loss)

$
24,459$
5,653$   32,778$   (6,836) Net income (loss) per share: Basic

$
.62$
.18$
.90$
(0.23) Diluted

$
.56$
.17$
.83$
(0.23) Weighted-average common shares used in computing   net income (loss) per share: Basic

39,45631,15536,34330,018 Diluted

43,40533,30539,41130,018JAZZ PHARMACEUTICALS, INC.SUMMARY OF PRODUCT SALES, NET(In thousands)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009Xyrem

$
42,931$
31,644$ 142,630$   96,763Luvox CR

9,4265,67527,37618,345Total

$
52,357$
37,319$ 170,006$ 115,108JAZZ PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)December 31,December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$
44,794$
5,595Restricted cash

4002,988Accounts receivable, net of allowances

22,08112,313Inventories

5,0463,426Prepaid expenses

1,8581,653Other current assets

279979Total current assets

74,45836,954Property and equipment, net

6901,124Intangible assets, net

22,03329,858Goodwill

38,21338,213Other long-term assets

3351,247Total assets

$
35,729$
7,396LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current liabilities:Revolving credit facility

$
7,350$
9,399Accounts payable

3,0492,158Accrued liabilities

23,5721
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... Calif., Feb. 25, 2011 Accuray Incorporated ... the field of radiosurgery, announced today that its Senior Vice ... was named "Best General Counsel, Small Public Company" by the ... San Francisco Business Times as part of their ,Best ...
... Landauer, Inc. (NYSE: LDR ) announced today that ... $0.55 per share for the second quarter of fiscal 2011.  The ... record on March 11, 2011. About Landauer ... analytical services to determine occupational and environmental radiation exposure and is ...
Cached Medicine Technology:Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 2Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 3Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 4
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality ... Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its ... care providers. 24/7 Care At Home’s agency is one of three top Orange County ...
(Date:7/30/2015)... ... ... The need for accessibility is never greater than when we find ourselves ... as visiting friends and family during these critical moments, hospitals around the Pennsylvania region ... by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series A ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate ... collaboration, OncLive’s editorial and marketing groups will help spread the news about the ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is ... Tool That Increases Training Capability , World renown body weight trainer, Paul ... http://www.Zejax.com ), that dramatically increases a person’s training capability. , The American College ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... ... services, announced today that the latest issue of Inclusive™ magazine, its multimedia publication ... platforms. The digital edition of the new issue, Volume 6, Issue 2, as ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... Benefit from Fosamax, Boniva, Zometa does not apply to obese ... types of bone-building drugs used to prevent and treat osteoporosis ... research. , The study, which included 6,000 Wisconsin women aged ... such as Fosamax, Boniva and Zometa for more than two ...
... ... wireless fitness sector. , ... Cochrane, Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), ... ANT+ Alliance. A noted leader in the design and manufacturing of sport ...
... Twelve children ... attorneys like David Perecman understand frustration of the families. , ... New York, NY (PRWEB) March 5, 2010 -- The U.S. ... by Maclaren. However, as reported by the New York Post , this was ...
... ... partnership with leading SolidWorks and Agile PLM reseller GoEngineer to distribute DesignState Enterprise PDM ... to manage engineering data and collaborate across the enterprise with Oracle,s powerful Agile ... ...
... ... in the U.S., according to the Centers for Disease Control (CDC). , ... Charleston, SC (PRWEB) March 5, ... Infections (HAIs) and they have generated much attention over the last decade. Studies have ...
... ... Mikel J. Harry, the world renowned co-creator of Six Sigma and national ... achievement to the point of breakthrough – and beyond. In this ... can envision, plan and achieve extraordinary things. The Great Discovery® is a ...
Cached Medicine News:Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:Defective Child Product Recall Involves New York Personal Injury Attorneys 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 3Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma 2
... the use of plates and screws in the treatment ... pins in the forearm or ankle is not a ... lock the pins or hold them in place. A ... out of the implant. The SST® (Stainless Steel Taper) ...
... 36 cc and 73 grams, the Epic ... care and simplified follow-up. The Epic HF ... 30 joule (delivered energy) biventricular ICD. Small ... HF ICD features advanced resynchronization parameters along ...
... has greatly enhanced the stabilization ... Biomet Low Profile Tibial Nail ... treatment of unstable fractures, tibial ... pathologic or impending fractures but ...
The Charlotte Shoulder™ System address arthroscopic, mini-open and open procedures with time saving instrumentation....
Medicine Products: